This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Coagulation and haemorrhagic disorders
  • /
  • Andexanet alfa for reversal of factor Xa inhibitor...

Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence

Read time: 1 mins
Published:1st Nov 2019
Author: Abdulrehman J, Eikelboom JW, Siegal DM.
Availability: Pay for access, or by subscription
Ref.:Future Cardiol. 2019;15(6):395-404.

Direct oral anticoagulants are associated with lower rates of bleeding than vitamin K antagonists, but life-threatening bleeding still occurs. Andexanet alfa is a catalytically inactive recombinant modified human factor Xa molecule that reverses the anticoagulant effect of direct and indirect acting factor Xa inhibitors. In the ANNEXA-4 study, treatment with andexanet was associated with a 92% reduction in median anti-Xa activity levels and excellent or good hemostasis in 82% of patients presenting with serious bleeding while receiving apixaban or rivaroxaban. In this review, we discuss the burden of bleeding in anticoagulated patients and the need for reversal agents, review the mechanism of action of andexanet and critically evaluate the evidence for its efficacy and safety.


Read abstract on library site

Access full article